Geode Capital Management
SXTC icon

Geode Capital Management’s China SXT Pharmaceuticals SXTC Stock Holding History

Geode Capital Management’s Portfolio SXTC Stock Details SXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4
Closed -$85.9K – 4597
2025
Q4 		$85.9K Hold
4
– – ﹤0.01% 4129
2025
Q3 		$85.3K Buy
+4
New +$79K ﹤0.01% 4170
2022
Q2 		– Hold
0
– -$7K – 5034
2022
Q1 		– Hold
0
– – – 4968
2021
Q4 		– Hold
0
– – – 4951
2021
Q3 		– Hold
0
– – – 4831
2021
Q2 		– Hold
0
– – – 4682
2021
Q1 		– Hold
0
– – – 4407
2020
Q4 		– Hold
0
– – – 4211

Other funds holding SXTC

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management's SXTC Position: Q1 2026 in Review

Geode Capital Management sold out of China SXT Pharmaceuticals (SXTC) in Q1 2026, closing a stake of 4 shares — an estimated $85.9K sold.

Geode Capital Management first reported a position in SXTC in Q3 2025 and held it in 2 quarters. The position peaked at $85.9K in Q4 2025. 1 fund tracked by Wall St. Rank holds SXTC as of Q1 2026.

  • Geode Capital Management reported no remaining China SXT Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Geode Capital Management sold 4 China SXT Pharmaceuticals shares in Q1 2026, an estimated $85.9K.
  • Geode Capital Management first reported a position in China SXT Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Geode Capital Management's China SXT Pharmaceuticals position peaked at $85.9K in Q4 2025.
  • 1 fund tracked by Wall St. Rank held China SXT Pharmaceuticals as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.